CVS Health fell short on third-quarter profit, but it posted strong sales and the health care ... Advertisement Article continues below this ad Prem Shah, who joined the company in 2013, will lead CVS ...

Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some ...

Thousands of cold and flu products could be on the chopping block after the FDA proposed to pull medications from store shelves that contain phenylephrine.

U.S. equities were mixed at midday with the tech sector getting a big boost from Netflix, which reported strong quarterly earnings. Intel shares advanced on a report it was looking for an investor ...

Free shipping is one of the best reasons to be a Prime member -- but we're here to tell you about all the other, lesser-known ...

Welcome to the Moderna third quarter 2024 conference call. [Operator instructions] Please be advised today's conference is ...

J.P. Morgan analyst Lisa Gill maintained a Buy rating on CVS Health (CVS – Research Report) yesterday and set a price target of $80.00. The company’s shares closed yesterday at $54.03. Gill covers the ...

On Friday, CVS Health ... The pharmacy giant is also backing away from the fiscal year 2024 issued during the second-quarter earnings release. The company reported second-quarter sales of $91. ...

CVS Health (CVS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Allen Lutz ...

CVS expects elevated medical costs to continue to pressure its performance this year, “and as a result we are not providing a ...